StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Goldman Sachs Sees Catalysts for Allergen (AGN) and Adds to Conviction Buy List
May 13, 2016 6:37 AM
(Updated - May 13, 2016 8:58 AM EDT)Goldman Sachs upgraded Allergen (NYSE: AGN) from Buy to Conviction Buy, with a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS View
Hot Comments
Upgrades
Next Articles
Allergan (AGN) Says Pivotal Trials for OCUN-009 and OCUN-010 Met Primary, Secondary Endpoints
May 16, 2016 7:16 AM
Mizuho Securities Remains Sidelined on Allergan (AGN) following 1Q Earnings; PT to $232
May 13, 2016 6:52 AM